156P Liver metastases correlate with shortened survival and increased dissociate response in patients treated with T cell engagers
48 h Inpatient (n[58) Cycle 1 CRS*, n (%) Grade 2, n (%) Grade 3, n (%) Grade 4, n (%) Time to onset from last dose, median hours (Q1, Q3) Time to resolution, median days (95% CI) 18 (60.0) 3 (10.0)0 ( 0 ) 0 (0) 10.6 (7.2,17.2) 3.0 (3.0, 4.0) 36 (62.1) 12 (20.7) 1 (1.7) 1 (1.7) 15.1 (8.6, 25.5) 3.0 (2.0, 3.0) Patients visiting the hospital or emergency room (ER) in cycle 1 for AEs, n (%) Hospitalization events, n ER visit events, n Duration of hospitalization or ER visits for AEs, median days (Q1, Q3) 8 (26.7) 6 2 4.5 (2.0, 5.0) 20 (34.5) 29 0 v3.0 (2.0, 5.0) * Highest grade CRS per subject.Conclusions: There were no major differences in safety outcomes following tarlatamab administration with 6-8 h outpatient versus 48 h inpatient monitoring in cycle 1.
Authors
- Adrien Mouren
- A. Marabelle
- Noé Herbel (ORCID: https://orcid.org/0009-0002-9788-7471)
- Matthieu Roulleaux Dugage (ORCID: https://orcid.org/0000-0003-3192-2342)
- Clara Helal (ORCID: https://orcid.org/0000-0002-7318-9962)
- Rastislav Bahleda (ORCID: https://orcid.org/0009-0001-8245-0544)
- S. Champiat
- S. Postel-Vinay
- V. Goldschmidt
- S. Ammari
- Y. Loriot
- A. Gazzah
- Clémence Henon (ORCID: https://orcid.org/0000-0001-7893-3116)
- C. Massard
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- K. Ouali
- Roger Sun (ORCID: https://orcid.org/0000-0001-9866-6449)
- Capucine Baldini
- F-X. Danlos
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100785
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00